Moreover, the high expression of the TIGIT ligand on leukemic cells may be a mechanism of immune evasion [203], and “in vitro” studies in AML cell lines or in primary AML cells demonstrated that blocking the TIGIT-CD155/CD112 axis may improve anti-leukemia immune response [198]. This evidence concerns the gene PVR and acute myeloid leukemia.